Upadacitinib was administered in clinical studies up to doses equivalent in daily AUC to 60 mg extended-release once daily. Adverse reactions were comparable to those seen at lower doses and no specific toxicities were identified. Approximately 90% of upadacitinib in the systemic circulation is eliminated within 24 hours of dosing (within the range of doses evaluated in clinical studies). In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
